Clinical Trial Update: Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Palbociclib as second-line therapy in CCND gene amplification–positive recurrent stage IV squamous cell lung cancer (Phase 2/Phase 3; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Lung Carcinoma

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: CCND1 Gene Amplification, CCND2 Gene Amplification | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-05-27